logo
Plus   Neg
Share
Email

Vertex: European Commission Approves KALYDECO To Treat Infants With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (VRTX) announced the European Commission has granted approval of the label extension for KALYDECO (ivacaftor) granules to include
the treatment of infants with cystic fibrosis ages 4 months and older. The company said the label update is based on data from a cohort in the 24-week phase 3 open-label safety study (ARRIVAL) consisting of six children with cystic fibrosis ages four months to less than six months who have eligible gating mutations.

KALYDECO will be now available to additional eligible patients in Germany and will be available shortly in countries that have entered into long-term reimbursement agreements with Vertex, including the UK, Denmark and the Republic of Ireland.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Church & Dwight Co., Inc. is recalling select vitafusion gummy products due to isolated manufacturing issue, the U.S. Food and Drug Administration said. The recall was initiated after the company's investigation of two consumer reports identified the possible presence of a metallic mesh material in product lots manufactured in a four-day period between October 29 and November 3, 2020. Shares of Netflix Inc. (NFLX) tanked 10% in extended trading session on Tuesday after the online-video streaming giant's first-quarter subscriber additions fell short of expectations. Netflix added 3.98 million subscribers globally in the quarter, far below its forecast of 6.00 million, to end the... Tech giant Apple Inc. (AAPL) on Tuesday held its first product launch event of the year and unveiled new iMac and iPad Pro, which are powered by the latest M1 chips. The Cupertino, California-based company also unveiled AirTag, a lost-device tracking gadget, and an upgraded Apple TV 4K with a new...
Follow RTT